CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0435 (clinicaltrials.gov NCT No: NCT01833039)
Title:An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Principal Investigator:Michael Wang
Treatment Agent:Ibrutinib
Study Status:Closed
Study Description:The goal of this clinical research study is to provide patients who have
relapsed or refractory MCL with early access to an investigational drug called
ibrutinib (also called PCI-32765) and to collect safety information about the
drug.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:N/A
Treatment Agents:Ibrutinib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Janssen Research and Development
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults